Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 0 completed trials have results

Key Signals

4 recruiting

Enrollment Performance

Analytics

Early Phase 1

3(75.0%)

N/A

1(25.0%)

4Total

Early Phase 1(3)

N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials

NCT07343791Early Phase 1Recruiting

Efficacy and Safety Study of DC-CIK Cell Therapy Combined With Epaloliposide, Vortexil, and Regorafenib as Third-line Treatment for Advanced Colorectal Cancer.

Role: lead

NCT06828341Early Phase 1Recruiting

A Single-arm, Open, Exploratory Clinical Study of Allogeneic CAR-T Cells in the Treatment of Relapsed/Refractory Brain Gliomas With Positive CD70 Expression

Role: lead

NCT06496724Not ApplicableRecruiting

A Clinical Study of Albumin-bound Paclitaxel/Granulocyte-based Therapy for Recurrent/Metastatic Breast Cancer

Role: lead

NCT06431529Early Phase 1Recruiting

A Study of Tumor Neoantigen-specific T Cells in the Treatment of Advanced Solid Tumors

Role: lead

All 4 trials loaded